查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933132

全球生物列印材料市场预测（至2034年）：按组件、应用、最终用户和地区划分

Bioprinting Material Market Forecasts to 2034 - Global Analysis By Component (Hydrogels, Extracellular Matrices (ECM), Living Cells, Support Materials/Sacrificial Materials, and Other Biomaterials), Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2026 年，全球生物列印材料市场价值将达到 20.1 亿美元，到 2034 年将达到 99.4 亿美元，在预测期内的复合年增长率为 22.1%。

生物列印材料市场专注于用于3D列印组织和生物结构的生物墨水、水凝胶、聚合物和细胞相容性材料。该市场为研究实验室、製药公司和再生医学开发商提供支援。成长要素包括组织工程的进步、个人化医疗投资的增加、对替代药物测试模型的需求、干细胞研究的进展以及在器官建模、创伤治疗和生物医学研究等领域应用的不断扩展。

据美国国立卫生研究院 (NIH) 称，全球每年在再生医学和组织工程研究方面的投资超过 25 亿美元。

利用3D生物列印组织扩大药物发现与测试的研发

领先的製药公司正从传统的二维细胞培养和存在伦理争议的动物实验转向高精度生物打印结构。这些三维模型具有更优异的生理相关性，能够更精确地进行药物毒性筛检和代谢分析。在临床前阶段及早发现潜在的失败案例，有助于企业大幅降低研发成本并缩短上市时间。这种向先进体外测试的转变，也确保了对高品质生物墨水和专用生物列印材料的持续需求。

生物墨水和活细胞研究成本过高

开发能够在结构完整性和生物活性之间保持微妙平衡的生物墨水，需要复杂的化学成分和严格的纯化过程。此外，取得和维持特定的人类原代细胞和干细胞会显着增加研究预算的开支。对于许多学术机构和小规模生技公司而言，这些持续的支出构成了限制，并减缓了实验检验的步伐。这种经济压力往往将生物列印技术的应用限制在高预算计划中，阻碍了其在众多对价格敏感的医疗领域的广泛商业化应用。

化妆品检测与个人化医疗

随着国际社会对化妆品动物试验的禁令不断扩大，化妆品产业正转向生物列印皮肤模型来评估成分的安全性和有效性。同时，个人化医疗的兴起为利用患者自身细胞列印客製化组织移植物和晶片器官模型提供了一个独特的细分市场。这些客製化解决方案最大限度地降低了移植排斥的风险，并实现了个人化的药物敏感性测试。此类应用蕴藏着巨大的未开发收入来源，并有可能重新定义标准的临床和工业实践。

大规模生产的可扩展性和可重复性有限

生物列印本质上是一个高精度、耗时的过程，且面临产量限制。确保所有生物列印构建体在大规模批量生产中保持相同的细胞分布和结构密度是一项技术挑战。不同批次材料的差异以及环境条件的变化会导致结果的变异性，这对于临床应用而言是不可接受的。如果自动化品管和高速多喷头列印技术没有突破性进展，生物列印产业将面临沦为小众研究工具而非再生医学标准生产方法的风险。

新冠疫情的影响：

新冠疫情为生物列印材料市场带来了挑战和机会。供应链中断和实验室关闭最初阻碍了常规研究活动。然而，这场危机加速了生物列印技术在疫苗研发和呼吸系统疾病建模的应用。研究人员利用3D生物列印的肺组织，在可控的、与人体相关的环境中阐明病毒感染机制并评估抗病毒效果。这种快速转变证明了该技术在医疗应变方面的有效性，并促使政府和私人投资者投入大量资金，以支持其在疫情后的发展。

预计在预测期内，水凝胶细分市场将占据最大的市场份额。

由于水凝胶作为活细胞结构支架的重要作用，预计在预测期内，水凝胶细分市场将占据最大的市场份额。水凝胶因其高含水量和生物相容性而备受青睐，这使其能够高度模拟人体组织的天然细胞外基质。水凝胶的多功能性使其能够与各种生长因子和讯号分子结合，从而促进细胞增殖和分化。此外，能够响应热或化学刺激的「智慧」水凝胶的开发，进一步拓展了其应用范围。

预计在预测期内，生物製药和生技公司板块的复合年增长率将最高。

预计在预测期内，生物製药和生技公司板块将呈现最高的成长率，因为这些公司正积极将生物列印技术整合到其研发开发平臺中。对更有效率药物开发流程的需求正推动这些公司大力投资于3D细胞培养系统，该系统能够提供比传统方法更准确的预测数据。此外，生物列印材料供应商与生物技术公司之间的策略合作也日益普遍，旨在为肿瘤学和神经病学等特定治疗领域开发专有生物墨水。全球对个人化治疗方案和再生医学日益增长的需求，进一步推动了该板块的快速扩张。

占比最大的地区：

预计北美将在预测期内占据最大的市场份额。这主要得益于该地区先进的医疗保健基础设施和对生命科学领域的巨额投资。美国和加拿大拥有众多产业巨头和顶尖研究型大学，为技术创新建立了强大的生态系统。此外，有利的法规结构和对先进医疗技术的早期应用也为其带来了竞争优势。该地区对再生医学的重视以及慢性病的高发生率，促使生物列印组织解决方案的开发势在必行，这将确保北美继续在全球市场保持重要的收入来源地位。

年复合成长率最高的地区：

由于生物技术的快速发展和政府对医学研究支持力度的加大，预计亚太地区在预测期内将实现最高的复合年增长率。中国、印度和日本等国正大力投资医疗现代化和医疗设备製造的本土化。该地区日益老化的人口以及慢性病的不断增多，催生了对创新器官和组织替代疗法的巨大需求。此外，临床试验成本低廉且监管透明度的提高，也促使全球生物列印公司在亚洲拓展业务，从而推动了前所未有的市场成长。

免费客製化服务资讯：

购买此报告后，您将获得以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 基于产品系列、地域覆盖范围和策略联盟对主要参与者进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生物列印材料市场（按成分划分）

  • 水凝胶
    • 天然水凝胶
    • 合成水凝胶
    • 混合/水凝胶复合材料
  • 细胞外基质（ECM）
  • 活细胞
  • 辅助/牺牲材料
  • 其他生物材料

6. 全球生物列印材料市场（按应用划分）

  • 组织工程与再生医学
    • 骨/软骨
    • 皮肤及覆盖组织
    • 血管和心臟
    • 神经
    • 其他组织
  • 药物发现与开发
  • 癌症研究
  • 牙科应用
  • 化妆品和皮肤护理
  • 其他用途

7. 全球生物列印材料市场（依最终用户划分）

  • 研究和学术机构
  • 生物製药和生物技术公司
  • 医院和诊断中心
  • 受託研究机构（CRO）
  • 其他最终用户

8. 全球生物列印材料市场（按地区划分）

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十章：企业概况

  • CELLINK AB
  • Advanced BioMatrix, Inc.
  • CollPlant Biotechnologies Ltd.
  • Organovo Holdings, Inc.
  • 3D Systems, Inc.
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Corning Incorporated
  • Lonza Group AG
  • FUJIFILM Corporation
  • Bio-Techne Corporation
  • Aspect Biosystems Ltd.
  • Gelita AG
  • Rousselot BV
Product Code: SMRC33700

According to Stratistics MRC, the Global Bioprinting Material Market is accounted for $2.01 billion in 2026 and is expected to reach $9.94 billion by 2034 growing at a CAGR of 22.1% during the forecast period. The bioprinting material market focuses on bioinks, hydrogels, polymers, and cell-compatible materials used in 3D printing tissues and biological structures. It supports research laboratories, pharmaceutical companies, and regenerative medicine developers. Growth is driven by advances in tissue engineering, increasing investment in personalized medicine, demand for alternative drug-testing models, progress in stem cell research, and expanding applications in organ modeling, wound healing, and biomedical research.

According to the U.S. National Institutes of Health (NIH), more than USD 2.5 billion annually is invested globally in regenerative medicine and tissue engineering research.

Market Dynamics:

Driver:

Growing R&D in drug discovery and testing using 3D bioprinted tissues

Pharmaceutical giants are increasingly transitioning from traditional 2D cell cultures and ethically sensitive animal testing toward high-fidelity bioprinted constructs. These 3D models offer superior physiological relevance, allowing for more accurate toxicity screening and metabolic profiling of drug candidates. By identifying potential failures earlier in the preclinical phase, companies significantly reduce development costs and time-to-market. This shift toward advanced in vitro testing ensures a sustained demand for high-quality bioinks and specialized bioprinting materials.

Restraint:

Extremely high cost of research-grade bioinks and living cells

Developing bioinks that maintain the delicate balance between structural integrity and biological viability requires complex chemical formulations and rigorous purification processes. Additionally, the procurement and maintenance of specific human primary cells and stem cells add substantial overhead to research budgets. For many academic institutions and smaller biotechnology startups, these recurring expenses can be restrictive, slowing the pace of experimental validation. This financial pressure often limits the use of bioprinting to high-budget projects, hindering broader commercialization across various price-sensitive medical sectors.

Opportunity:

Expansion into cosmetic testing and personalized medicine

With increasing global bans on animal testing for beauty products, the cosmetic industry is turning to bioprinted skin models to evaluate ingredient safety and efficacy. Simultaneously, the rise of personalized medicine offers a unique niche where patient-derived cells are used to print custom tissue grafts and organ-on-a-chip models. These tailored solutions minimize the risk of transplant rejection and allow for individualized drug sensitivity testing. Such applications represent a massive, untapped revenue stream that could redefine standard clinical and industrial practices.

Threat:

Limited scalability and reproducibility for mass production

Bioprinting is inherently a high-precision, time-intensive process that struggles with throughput limitations. Ensuring that every bioprinted construct maintains identical cellular distribution and structural density across large batches is technically challenging. Variations in material batches or environmental conditions can lead to inconsistent results, which is unacceptable for clinical-grade applications. Without significant breakthroughs in automated quality control and high-speed multi-nozzle printing technologies, the industry risks remaining a niche research tool rather than a standard manufacturing method for regenerative medicine.

Covid-19 Impact:

The COVID-19 pandemic presented both challenges and opportunities for the bioprinting material market. Initially, disruptions in the supply chain and laboratory closures impeded standard research activities. However, the crisis expedited the implementation of bioprinting for vaccine development and respiratory disease modeling. Researchers employed 3D bioprinted lung tissues to investigate viral infection mechanisms and evaluate antiviral efficacy in a controlled, human-relevant setting. This urgent transition underscored the technology's efficacy in emergency medical response, consequently drawing substantial government funding and private investment that has supported post-pandemic expansion.

The hydrogels segment is expected to be the largest during the forecast period

The hydrogels segment is expected to account for the largest market share during the forecast period due to its indispensable role as a structural scaffold for living cells. Hydrogels are favored for their high water content and biocompatibility, which closely mimic the natural extracellular matrix of human tissues. Their versatility allows for the incorporation of various growth factors and signaling molecules, facilitating cell proliferation and differentiation. Furthermore, the development of "smart" hydrogels that respond to thermal or chemical stimuli has broadened their application scope.

The biopharmaceutical & biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharmaceutical & biotechnology companies segment is predicted to witness the highest growth rate as these entities aggressively integrate bioprinting into their discovery pipelines. The push for more efficient drug development processes is driving these companies to invest heavily in 3D cell culture systems that provide better predictive data than traditional methods. Moreover, strategic collaborations between bioprinting material providers and biotech firms are becoming commonplace, aimed at developing proprietary bioinks for specific therapeutic areas like oncology and neurology. The rising global demand for personalized therapeutic solutions and regenerative medicine further fuels this segment's rapid expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, primarily driven by its sophisticated healthcare infrastructure and substantial investment in life sciences. The presence of major industry players and leading research universities in the United States and Canada fosters a robust ecosystem for technological innovation. Additionally, favorable regulatory frameworks and the early adoption of advanced medical technologies provide a competitive edge. The region's focus on regenerative medicine and the high prevalence of chronic diseases necessitate the development of bioprinted tissue solutions, ensuring North America remains the primary revenue generator for the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to rapid advancements in biotechnology and increased government support for medical research. Countries like China, India, and Japan are investing heavily in healthcare modernization and the indigenization of medical device manufacturing. The growing geriatric population in this region, coupled with a rise in chronic conditions, is creating a massive demand for innovative organ and tissue replacement therapies. Furthermore, lower clinical trial costs and improving regulatory clarity are attracting global bioprinting companies to expand their footprint in Asia, leading to an unprecedented rate of market growth.

Key players in the market

Some of the key players in Bioprinting Material Market include CELLINK AB, Advanced BioMatrix, Inc., CollPlant Biotechnologies Ltd., Organovo Holdings, Inc., 3D Systems, Inc., Merck KGaA, Thermo Fisher Scientific Inc., Sartorius AG, Corning Incorporated, Lonza Group AG, FUJIFILM Corporation, Bio-Techne Corporation, Aspect Biosystems Ltd., Gelita AG, and Rousselot B.V.

Key Developments:

In December 2025, CELLINK (BICO Group) unveiled a new bioink portfolio designed for vascularized tissue printing, targeting pharmaceutical R&D.

In October 2025, Organovo announced progress in 3D-printed liver tissue models, expanding its bioprinting material applications for drug testing.

In August 2025, 3D Systems launched collagen-based bioprinting materials, strengthening its healthcare additive manufacturing division.

Components Covered:

  • Hydrogels
  • Extracellular Matrices (ECM)
  • Living Cells
  • Support Materials/Sacrificial Materials
  • Other Biomaterials

Applications Covered:

  • Tissue Engineering & Regenerative Medicine
  • Drug Discovery & Development
  • Cancer Research
  • Dental Applications
  • Cosmetic & Dermal Applications
  • Other Applications

End Users Covered:

  • Research & Academic Institutions
  • Biopharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostic Centers
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bioprinting Material Market, By Component

  • 5.2 Hydrogels
    • 5.2.1 Natural Hydrogels
    • 5.2.2 Synthetic Hydrogels
    • 5.2.3 Hybrid/Hydrogel Composites
  • 5.3 Extracellular Matrices (ECM)
  • 5.4 Living Cells
  • 5.5 Support Materials/Sacrificial Materials
  • 5.6 Other Biomaterials

6 Global Bioprinting Material Market, By Application

  • 6.1 Introduction
  • 6.2 Tissue Engineering & Regenerative Medicine
    • 6.2.1 Bone & Cartilage
    • 6.2.2 Skin & Integumentary
    • 6.2.3 Vascular & Cardiac
    • 6.2.4 Neural
    • 6.2.5 Other Tissues
  • 6.3 Drug Discovery & Development
  • 6.4 Cancer Research
  • 6.5 Dental Applications
  • 6.6 Cosmetic & Dermal Applications
  • 6.7 Other Applications

7 Global Bioprinting Material Market, By End User

  • 7.1 Introduction
  • 7.2 Research & Academic Institutions
  • 7.3 Biopharmaceutical & Biotechnology Companies
  • 7.4 Hospitals & Diagnostic Centers
  • 7.5 Contract Research Organizations (CROs)
  • 7.6 Other End Users

8 Global Bioprinting Material Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 CELLINK AB
  • 10.2 Advanced BioMatrix, Inc.
  • 10.3 CollPlant Biotechnologies Ltd.
  • 10.4 Organovo Holdings, Inc.
  • 10.5 3D Systems, Inc.
  • 10.6 Merck KGaA
  • 10.7 Thermo Fisher Scientific Inc.
  • 10.8 Sartorius AG
  • 10.9 Corning Incorporated
  • 10.10 Lonza Group AG
  • 10.11 FUJIFILM Corporation
  • 10.12 Bio-Techne Corporation
  • 10.13 Aspect Biosystems Ltd.
  • 10.14 Gelita AG
  • 10.15 Rousselot B.V.

List of Tables

  • Table 1 Global Bioprinting Material Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Bioprinting Material Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Bioprinting Material Market Outlook, By Hydrogels (2023-2034) ($MN)
  • Table 4 Global Bioprinting Material Market Outlook, By Natural Hydrogels (2023-2034) ($MN)
  • Table 5 Global Bioprinting Material Market Outlook, By Synthetic Hydrogels (2023-2034) ($MN)
  • Table 6 Global Bioprinting Material Market Outlook, By Hybrid / Hydrogel Composites (2023-2034) ($MN)
  • Table 7 Global Bioprinting Material Market Outlook, By Extracellular Matrices (ECM) (2023-2034) ($MN)
  • Table 8 Global Bioprinting Material Market Outlook, By Living Cells (2023-2034) ($MN)
  • Table 9 Global Bioprinting Material Market Outlook, By Support / Sacrificial Materials (2023-2034) ($MN)
  • Table 10 Global Bioprinting Material Market Outlook, By Other Biomaterials (2023-2034) ($MN)
  • Table 11 Global Bioprinting Material Market Outlook, By Application (2023-2034) ($MN)
  • Table 12 Global Bioprinting Material Market Outlook, By Tissue Engineering & Regenerative Medicine (2023-2034) ($MN)
  • Table 13 Global Bioprinting Material Market Outlook, By Bone & Cartilage (2023-2034) ($MN)
  • Table 14 Global Bioprinting Material Market Outlook, By Skin & Integumentary (2023-2034) ($MN)
  • Table 15 Global Bioprinting Material Market Outlook, By Vascular & Cardiac (2023-2034) ($MN)
  • Table 16 Global Bioprinting Material Market Outlook, By Neural (2023-2034) ($MN)
  • Table 17 Global Bioprinting Material Market Outlook, By Other Tissues (2023-2034) ($MN)
  • Table 18 Global Bioprinting Material Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 19 Global Bioprinting Material Market Outlook, By Cancer Research (2023-2034) ($MN)
  • Table 20 Global Bioprinting Material Market Outlook, By Dental Applications (2023-2034) ($MN)
  • Table 21 Global Bioprinting Material Market Outlook, By Cosmetic & Dermal Applications (2023-2034) ($MN)
  • Table 22 Global Bioprinting Material Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 23 Global Bioprinting Material Market Outlook, By End User (2023-2034) ($MN)
  • Table 24 Global Bioprinting Material Market Outlook, By Research & Academic Institutions (2023-2034) ($MN)
  • Table 25 Global Bioprinting Material Market Outlook, By Biopharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 26 Global Bioprinting Material Market Outlook, By Hospitals & Diagnostic Centers (2023-2034) ($MN)
  • Table 27 Global Bioprinting Material Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 28 Global Bioprinting Material Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.